Kura Oncology (KURA) FCF Margin (2025 - 2026)
Kura Oncology (KURA) posted quarterly FCF Margin of 470.75% for Q1 2026, up 4115.0% year-over-year from 11.17% in Q1 2025, and down 170.99% quarter-over-quarter from 663.08% in Q4 2025.
Kura Oncology (KURA) FCF Margin (2025 - 2026) Analysis & Trends
Kura Oncology (KURA) has reported FCF Margin for 2 consecutive years, with 470.75% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin rose 4115.0% year-over-year to 470.75%; the TTM figure through Mar 2026 stood at 117.9% (changed N/A YoY), while the FY2025 annual figure was 104.76%, down 35316.0% from the prior year.
- FCF Margin slipped to 470.75% in Q1 2026 per KURA's latest filing, from 663.08% in the prior quarter.
- Across five years, FCF Margin topped out at 663.08% in Q4 2025 and bottomed at 511.9% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Kura Oncology | 966.11 Mn | 966.11 Mn | 20.63 Mn | -302.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -302.79% |
| Mar 31, 2026 | -470.75% |
| Dec 31, 2025 | 663.08% |
| Sep 30, 2025 | -400.93% |
| Jun 30, 2025 | -197.77% |
| Mar 31, 2025 | -511.90% |